605507 Guobang Pharma Ltd.
- 20.53
- +0.05+0.24%
About Guobang Pharma Ltd. Company
The company is a pharmaceutical manufacturing company that faces the global market, has multiple varieties, and has the ability to self-produce a variety of key intermediates. It is an important participant in the global chemical manufacturing industry chain and is one of the top 100 enterprises in China's pharmaceutical industry. The company is mainly engaged in R&D, production and sales of related products in the field of pharmaceuticals and animal health products. Among them, the pharmaceutical sector covers pharmaceutical raw materials, key pharmaceutical intermediates and preparations, and the animal health products sector covers animal protection raw materials, animal protection additives and formulations. Since its establishment, the company has been deeply involved in the fields of pharmaceuticals and animal health products, adhering to pharmaceutical and chemical technology as the core, deepening the development of regional main functional areas, and following the path of high-quality development. The company's main products include azithromycin, clarithromycin, roxithromycin, ciprofloxacin hydrochloride, reducing agent series products, advanced amine series products, fluorfenicol, doxycycline, enrofloxacin, etc. The company has successively won “China's Top 100 Chemical and Pharmaceutical Industry Enterprises with Comprehensive Strength”, “China Pharmaceutical Industry Top 100 Enterprises” by the All-China Federation of Industry and Commerce Pharmaceutical Industry Chamber of Commerce, “High Quality Suppliers and Partners in the International Market” of the China Chamber of Commerce for Import and Export of Medicines and Health Products, “China's Top 10 Western Pharmaceutical Ingredients Industry Member Export Companies”, “Outstanding Academician Expert Workstation” by the China Federation of Industry and Commerce Pharmaceutical Industry Chamber of Commerce “China's Top 100 Pharmaceutical Manufacturing Companies for 2022 - 2023”, “China Pharmaceutical Industry Growth Top 50”, “China Pharmaceutical Industry Growth Top 50”, “China Pharmaceutical Industry Growth Top 50” Honorary titles such as “Top 50 Enterprises” and “Leading Pharmaceutical Internationalization Enterprise”.
Company Profile
Company Executives
- Name
- Position
- Salary
- jiajun qiu
- Chairman, Directors, Director of the Strategy Committee
- 2.13M
- ligao yao
- Directors, VP
- 1.68M
- shixue liao
- Directors, President, Member of the Remuneration and Assessment Committee
- 2.02M
- qibin li
- Directors, VP, Strategy Committee Member
- 1.80M
- yaqing zhu
- Directors, Nomination Committee Members, Audit Committee Member
- 1.55M
- yuda gong
- Directors, Board Secretary, Chief Financial Officer
- 1.55M
- mingchuan ren
- Independent Directors, Nomination Committee Members, Audit Committee Director
- 140.00K
- xiaoming wu
- Independent Directors, Strategy Committee Member, Audit Committee Member, Chairman of the Remuneration and Assessment Committee
- 140.00K
- chengjie zhang
- Independent Directors, Chairman of the Nomination Committee, Member of the Remuneration and Assessment Committee
- 140.00K
- deguang peng
- Securities Affairs Representative
- --
- zhongjian meng
- Chairman of the Supervisory Board, Auditors
- 1.29M
- cuicui liu
- Auditors
- 660.60K
- fangfang lv
- VP
- 1.92M
- zhiming lin
- Employee Supervisors
- 193.80K
No Data
